Biotherapeutics: Biotherapeutic products derived from recombinant DNA technology such as interferons, interleukins, and growth factors have provided a major advance in the safety and effectiveness of therapeutic peptides and proteins, and they have a successful record in treating many life-threatening and chronic diseases. Since contamination with unwanted pathogens can be greatly reduced and production volumes are expanded by the developed biotechnology, many more patients have increased access to biotherapeutic products. Technical issues such as the potential immunogenicity of active substances produced under differing manufacturing conditions must also be considered.